K Ravindra Chandrappa files substantial acquisition disclosure under SEBI Takeover Regulations
Under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Regulation 31(4) requires disclosure of substantial shareholding to the stock exchange and company. The filing by K Ravindra Chandrappa suggests acquisition of shares crossing material thresholds (typically 5%, 10%, 15%, 25%, or 55%). The absence of commercial details in the public article indicates the substantive terms are contained in the formal NSE filing document itself.
Why it mattersRegulation 31(4) disclosures signal a creeping acquisition or concert-party arrangement crossing the 5% threshold; counsel should verify whether the acquirer triggered open offer obligations or claimed exemptions (related party, creeping acquisition rules), as these gates determine whether a full-scale takeover bid follows.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives / Corporate Disclosures · official
- Bar & Bench (Primary Article)
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026